查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456938

嗜伊红性食道炎治疗市场－2024年至2029年预测

Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 125 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年，嗜伊红性食道炎治疗市值为379,961,000美元，复合年增长率为8.12%，到2029年市场规模将达到656,118,000美元。

嗜伊红性食道炎是一种慢性疾病。胃食道逆流症（GERD）和嗜伊红性食道炎通用的症状，例如胸痛和吞嚥困难。多年来，它被认为是一种常见于儿童的疾病，但现在可以登记的年轻人病例数量正在增加。嗜伊红性食道炎的常见症状是吞嚥困难、胸腔或上腹部疼痛、呕吐。

当食道充满称为嗜酸性粒细胞细胞的白血球时，就会发生嗜伊红性食道炎。这些嗜酸性粒细胞应该保留在胃肠道中，但如果它们在其他地方积聚，则会引起器官内的不适和发炎。

嗜伊红性食道炎II型发炎疾病的盛行率上升、治疗方法的进步以及与FDA认证核可药争夺先发优势等因素推动了嗜伊红性食道炎治疗市场的发展，预计该市场将受到激烈竞争的推动。嗜伊红性食道炎的许多需求支持了嗜伊红性食道炎药物产业的蓬勃发展。嗜伊红性食道炎的诊断标准有缺陷，因为它们依赖专家意见（胃肠病学家、过敏科医生和病理学家的共识）而不是证据。嗜伊红性食道炎的组织学标准目前尚不清楚，因为疾病活动性与患者症状之间没有相关性，需要反覆组织学检查才能确认疾病发作。

以下是成人和儿童嗜伊红性食道炎的症状。在成人中，症状包括未消化的食物逆流、咀嚼卡在食道的食物时胸痛以及咀嚼和吞嚥食物困难。在儿童中，一些常见症状包括吞嚥困难和食物卡在食道中，其他症状包括呕吐、腹痛、餵食困难和对药物反应迟钝。

市场驱动因素：

  • 加强对嗜酸性粒细胞相关疾病的宣导活动将推动市场成长。

正在设计和实施各种教育计划，以向公众和医疗相关人员提供有关嗜酸性粒细胞相关疾病的教育，预计这将支持市场扩张。嗜伊红性食道炎市场是由胃肠道发炎疾病的增加所推动的。过敏、食道内嗜酸性粒细胞积聚、吞嚥困难和食道内嵌塞的增加预计将推动嗜伊红性食道炎市场的成长。

  • 及时、快速核准的监管支援预计将推动市场成长。

监管支持和快速核准可能会显着促进嗜伊红性食道炎疾病治疗药物市场的发展。这些包括更快的药物开发、更快的市场进入、投资便利、快速通道和突破性治疗等指定项目以及临床试验设计的弹性。监管机构也特别考虑罕见疾病，简化监管途径并鼓励创新。这些因素促进了 EoE 治疗市场的成长，解决未满足的医疗需求，提供改善生命和挽救生命的治疗方法，并促进新治疗方法开发的创新。

市场限制因素：

  • 缺乏疾病意识和治疗可接受性可能会阻碍市场成长

全球嗜伊红性食道炎市场可能会因该地区缺乏疾病意识和治疗可接受性而受到阻碍。迄今为止，尚未核准针对嗜伊红性食道炎的特异性治疗方法。美国食品药物管理局（FDA）等监管机构对参与药物临床开发、製造、行销和分销的组织施加重要且严格的限制，使得获得药物核准耗时且困难。

北美预计将主导嗜伊红性食道炎治疗药物市场。

由于对降低气喘风险的药物和高端医疗保健的需求不断增加，预计北美将拥有最大的嗜伊红性食道炎治疗药物市场规模。由于导致嗜酸性粒细胞细胞疾病的过敏发生率不断增加，欧洲预计将成为嗜伊红性食道炎的第二大市场。由于非专利药厂商的意识和存在不断增强，亚太地区可能在预测期内占据嗜伊红性食道炎市场的最大市场占有率。

然而，高昂的治疗成本和缺乏患者资讯限制了中东、非洲和南美洲等国家的嗜伊红性食道炎市场。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章嗜伊红性食道炎治疗市场：依产品类型

  • 介绍
  • 仿单标示外药物
    • 市场机会趋势
    • 成长前景
    • 地域盈利
  • Budesonide奈德口服悬浮液
    • 市场机会趋势
    • 成长前景
    • 地理收益
  • FluticasoneODT
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 美泊利单抗
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 瑞利珠单抗
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 贝那利珠单抗
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 杜皮尔·纳布
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • Omalizumab
    • 市场机会和趋势
    • 成长前景
    • 地理收益

第六章嗜伊红性食道炎治疗市场：依通路分类

  • 介绍
  • 医院药房
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 零售药房
    • 市场机会和趋势
    • 成长前景
    • 地域盈利
  • 网路药房
    • 市场机会和趋势
    • 成长前景
    • 地域盈利

第七章嗜伊红性食道炎治疗市场：依地区

  • 介绍
  • 北美洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 按分销管道
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Ellodi Pharmaceuticals
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Sanof
  • Takeda Pharmaceutical Company Limited
  • Pfizer
简介目录
Product Code: KSI061612287

The eosinophilic esophagitis disease treatment market is evaluated at US$379.961 million for the year 2022 growing at a CAGR of 8.12% reaching the market size of US$656.118 million by the year 2029.

EoE (Eosinophilic esophagitis) is a disease of chronic type. Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis share symptoms such as chest pain and difficulty swallowing. It was considered a common disease in children for many years but has now grown in cases in young people that can be registered. Common symptoms of EOE are difficulty swallowing, pain in the chest cavity and upper abdomen, and vomiting.

The condition of eosinophilic Esophagitis occurs when the esophagus is filled with white blood cells, which are also known as eosinophils. These eosinophils should remain inside the digestive tract if they build up elsewhere, creating discomfort and inflammation inside the organ.

The market for eosinophilic esophagitis disease treatment is expected to be pushed by the rising prevalence of type II inflammatory illnesses, such as EoE, advancements in treatment approaches, and fierce competition among competitors for the first FDA-approved medicine to gain a first-mover advantage. EoE has a lot of needs, which is helping the eosinophilic esophagitis medication sector flourish. EoE diagnosis criteria are flawed since they are reliant on professional opinions (agreement among gastroenterologists, allergists, and pathologists) rather than evidence. Because there is no correlation between disease activity and patient symptoms, histologic criteria for EoE are currently unclear, and repeated tissue testing is required to confirm disease initiation.

The following are the symptoms of Eosinophilic Esophagitis in adults and children: In adults, symptoms are the backflow of undigested food, chest pain while chewing food that gets stuck in the esophagus, and difficulty in chewing and swallowing the food. In a child, some symptoms are common, like difficulty swallowing, and food getting stuck in the esophagus, while other symptoms in the child are vomiting, abdominal pain, difficulty eating, and no response to the medication.

MARKET DRIVER:

  • Increasing awareness campaigns for eosinophil-associated illnesses will bolster the growth of the market.

Various public and medical awareness programs have been designed and implemented to educate the public and medical community about eosinophil-related illnesses, which is expected to fuel market expansion. The market for eosinophilic esophagitis is being driven by an increase in the occurrences of digestive tract inflammatory illnesses. Eosinophilic esophagitis (EoE) market growth is expected to be boosted by increased allergies in the esophagus, eosinophil build-up, dysphagia, and impaction in the esophagus.

  • Regulatory support with timely and expedited approvals is expected to surge the market growth.

Regulatory support and expedited approvals can significantly boost the Eosinophilic Esophagitis (EoE) disease treatment market. This includes faster drug development, faster market access, encouraging investment, designation programs like Fast Track and Breakthrough Therapy, and flexibility in clinical trial design. Regulatory agencies also provide special considerations for rare diseases, streamline regulatory pathways, and encourage innovation. These factors contribute to the growth of the EoE treatment market, addressing unmet medical needs, providing life-improving or life-saving treatments, and fostering innovation in the development of novel treatment modalities.

MARKET RESTRAINTS:

  • Lack of disease awareness and treatment acceptability could hamper the market growth

The global eosinophilic esophagitis (EoE) market may be hampered by a lack of disease awareness and the acceptability of treatment for a given location. For the time being, no specific treatment for eosinophilic esophagitis has been approved. Obtaining regulatory approval for the drug is time-consuming and difficult, as regulatory agencies such as the US Food and Drug Administration (FDA) place significant and stringent restrictions on organizations involved in the clinical development, manufacture, marketing, and distribution of drugs.

North America is expected to dominate the Eosinophilic Esophagitis Treatment Market.

With the rising demand for asthma risk-reducing medications and high-end medical treatments, it is predicted that North America will have the biggest market volume in the Eosinophilic Esophagitis Treatment Market. Because of the increased occurrence of allergies that cause eosinophilic illnesses, Europe is expected to be the second-largest market for eosinophilic esophagitis (EoE). Due to growing awareness and the existence of generic companies, Asia-Pacific is likely to account for the biggest market share in the eosinophilic esophagitis (EoE) market in the forecasted period.

However, in places such as the Middle East, Africa, and South America, high therapeutic costs and a lack of patient information are limiting the eosinophilic esophagitis market.

Key development

  • September 2023- The FDA has approved Dupixent(R) (dupilumab) for Priority Review to treat children aged 1-11 with eosinophilic esophagitis (EoE). Dupixent is the first and only treatment in the U.S. approved for children and adults aged 12 and older with EoE, weighing at least 40kg. If approved, it would be the first and only treatment indicated in the U.S. for children aged 1-11.
  • May 2022- The FDA has approved Dupixent (dupilumab) as the first treatment for Eosinophilic Esophagitis (EoE), a chronic immune disorder affecting adults and pediatric patients aged 12 and above. EoE is a chronic inflammatory disorder characterized by difficulty swallowing, eating, and food sticking in the esophagus. Dupixent is a monoclonal antibody that inhibits part of the inflammatory pathway, making it the first FDA approval for a treatment for EoE.

Segmentation

By Product Type

  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Off-Label Drugs
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Budesonide Oral Suspension
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Fluticasone ODT
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Mepolizumab
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Reslizumab
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness
  • 5.7. Benralizumab
    • 5.7.1. Market Opportunities and Trends
    • 5.7.2. Growth Prospects
    • 5.7.3. Geographic Lucrativeness
  • 5.8. Dupilunab
    • 5.8.1. Market Opportunities and Trends
    • 5.8.2. Growth Prospects
    • 5.8.3. Geographic Lucrativeness
  • 5.9. Omalizumab
    • 5.9.1. Market Opportunities and Trends
    • 5.9.2. Growth Prospects
    • 5.9.3. Geographic Lucrativeness

6. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospital Pharmacies
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Retail Pharmacies
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Online Pharmacies
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Distribution Channel
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. United Kingdom
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Spain
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Indonesia
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Others
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Ellodi Pharmaceuticals
  • 9.2. AstraZeneca Plc
  • 9.3. Bristol-Myers Squibb Co
  • 9.4. GlaxoSmithKline Plc
  • 9.5. Sanof
  • 9.6. Takeda Pharmaceutical Company Limited
  • 9.7. Pfizer